# Purple Biotech Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Purple Biotech Ltd). ## Overview Purple Biotech Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing oncology immunotherapy candidates. Its work centers on a tri-specific antibody platform designed to activate both T cells and NK cells against solid tumors, with development programs carried out from its Rehovot, Israel base and funded through public-market capital. ## Products & services • CAPTN-3 tri-specific antibody platform • IM1240 lead oncology product candidate • IM1305 preclinical product candidate • Tumor-targeted immunotherapy discovery and development • AI-assisted antibody design collaborations - **Lead clinical development program** (70%) — CAPTN-3 and its lead candidate IM1240, which are being advanced as oncology immunotherapy assets. - **Preclinical pipeline** (20%) — Earlier-stage candidates such as IM1305 that broaden the platform beyond the lead program. - **Platform discovery and optimization** (10%) — Tri-specific antibody engineering and proprietary capping technology used to design tumor-selective molecules. - CAPTN-3 tri-specific antibody platform - IM1240 lead oncology product candidate - IM1305 preclinical product candidate - Tumor-targeted immunotherapy discovery and development - AI-assisted antibody design collaborations ## Customers Purple Biotech does not sell commercial medicines; its direct counterparties are research partners, clinical collaborators, and capital providers that support drug development. The eventual end customers for approved products would be oncology physicians, hospitals, and cancer patients, but today the business is primarily oriented toward advancing drug candidates through development milestones. Its collaborations also indicate engagement with external technology partners to accelerate antibody design. - **Capital market investors** (primary) — Buy equity exposure to the clinical-stage pipeline and platform value. - **Research and technology partners** (secondary) — Collaborate on design, optimization, and acceleration of antibody candidates. - **Clinical trial ecosystem** (secondary) — Hospitals, investigators, and CROs support development of oncology candidates. - **Future oncology providers** (emerging) — Would use approved therapies for solid-tumor treatment if programs succeed. - Research and development partners supporting antibody discovery - Clinical collaborators needed for oncology trial execution - Capital market investors funding clinical-stage development - Future oncology prescribers if candidates reach commercialization - Patients with solid tumors targeted by the platform ## Geography Purple Biotech is headquartered in Rehovot, Israel and is publicly listed on Nasdaq and the Tel Aviv Stock Exchange. Its development work is centered in Israel, while its capital access and investor base are international through U.S. and Israeli public markets. The company’s clinical and partnership footprint can extend beyond Israel as candidates progress into broader oncology development. - Headquartered in Rehovot, Israel - Listed on Nasdaq and TASE - Development activities centered in Israel - Investor access spans U.S. and Israel - Future trials and partnerships may be international ## Strategy Purple Biotech’s strategy is to advance a differentiated oncology platform built around conditionally activated tri-specific antibodies and to extend that platform into multiple drug candidates. It is also using external collaborations, including AI-enabled design partnerships, to improve discovery speed and molecule quality while broadening the pipeline. - **Advance lead oncology candidate** (short-term) — Clinical progress is the main driver of platform validation and future value creation. - **Develop a multi-asset platform** (medium-term) — A broader pipeline reduces dependence on a single program and increases partnering optionality. - **Use external technology collaboration** (short-term) — AI-enabled design can shorten discovery cycles and improve candidate quality. - Advance the CAPTN-3 platform into clinical development - Progress IM1240 as the lead program - Build a second program with IM1305 - Use proprietary capping to focus immune activity in tumors - Leverage AI collaborations to speed discovery - Expand value through oncology-focused partnerships ## Risks Purple Biotech faces the typical risks of a clinical-stage biotechnology company: programs may fail in preclinical or clinical development, timelines can be long and uncertain, and future value depends on successful validation of a narrow pipeline. As a public Israeli company with U.S. listing exposure, it also depends on capital markets access and continued Nasdaq compliance, while research partnerships and scientific execution remain critical to its strategy. - **Clinical development failure** [critical] — The pipeline is preclinical/clinical-stage, so efficacy or safety issues could halt programs. - **Capital market dependence** [high] — Biotech development requires ongoing funding before any product revenue exists. - **Listing and liquidity risk** [medium] — Maintaining exchange compliance is important for trading access and financing flexibility. - **Scientific development risk** [high] — Tri-specific antibodies and tumor-selective activation are technically complex to design and validate. - Clinical failure risk is high because pipeline assets are still early stage - Funding risk is material because development depends on external capital - Nasdaq listing compliance affects market access and investor liquidity - Scientific and translational risk is elevated in oncology immunotherapy - Partnership execution risk can delay discovery or candidate optimization ## Accounting As a clinical-stage biotech company, Purple Biotech’s results are shaped more by R&D expense, equity-linked financing instruments, and valuation judgments than by operating revenue. The reports also show fair-value accounting for warrants, share-based payment expense, lease liabilities, and post-employment benefit estimates, all of which can materially affect reported equity and earnings. - **Fair value of warrants** — Can materially affect periodic earnings and equity - **Share-based payment accounting** — Influences R&D and G&A expense - **R&D expensing** — Makes current-period losses reflect development intensity - **Lease liabilities** — Affects leverage and finance expense - **Post-employment benefit estimates** — Can move equity and operating costs - R&D expense drives reported results because the company has no product sales - Warrant valuation affects fair-value gains or losses in the income statement - Share-based compensation impacts operating expenses and equity reserves - Lease accounting affects balance sheet liabilities and finance costs - Post-employment benefit estimates depend on actuarial assumptions --- *Last updated: 2026-09-28T12:13:38.075321+00:00*